Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.57 |
| ▸ | FGR | P09769 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.57 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15258022 | 0.88 | SYK (0.74) | SYKJAK2LCKYES1LYN | |
| SCHEMBL14981627 | 0.87 | SYK (0.75) | SYKJAK2LCKYES1LYN | |
| SCHEMBL15631805 | 0.82 | SYK (0.77) | SYKKCNH2 | |
| SCHEMBL18863375 | 0.82 | SYK (0.77) | SYKKCNH2 | |
| SCHEMBL16202743 | 0.80 | SYK (0.70) | SYKJAK2LCKYES1LYN | |
| SCHEMBL2627154 | 0.80 | SYK (1.00) | SYK | |
| SCHEMBL16202701 | 0.79 | SYK (0.66) | SYKJAK2LCKYES1LYN | |
| SCHEMBL2627441 | 0.79 | SYK (0.64) | SYKJAK2LCKYES1LYN | |
| SCHEMBL16204582 | 0.79 | SYK (0.77) | SYKJAK2LCKYES1LYN | |
| SCHEMBL2627437 | 0.78 | SYK (0.65) | SYKJAK2LCKYES1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2782580-A1 | SELECTIVE KINASE INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013078468-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | SYK, BTK, LCK | SYK 1/4885JAK2 40/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.